PEPTONIC medical AB (publ) - Laporan Laba Rugi (TTM)

PEPTONIC medical AB (publ)
SE ˙ XSAT
SEK 0.00 0.00 (0.00%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi PEPTONIC medical AB (publ) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 14 21 31 35 33 32 29 34 39 44 44 43 41 39 33 29 27 20 19
Change (%) 50.66 45.11 12.29 -3.40 -5.54 -7.82 17.10 14.58 11.49 -0.08 -0.97 -6.15 -3.63 -14.90 -12.04 -8.01 -26.22 -2.62
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 4 8 12 14 14 13 11 15 17 20 21 21 21 22 19 16 12 8 5
Change (%) 94.17 49.02 10.97 3.00 -9.92 -11.94 32.42 16.81 18.18 3.42 -1.76 -0.18 5.88 -11.23 -17.34 -26.43 -28.31 -37.41
% of Revenue 29.87 38.50 39.54 39.08 41.67 39.73 37.96 42.92 43.76 46.38 48.01 47.63 50.65 55.65 58.05 54.55 43.62 42.39 27.24
Gross Operating Profit 10 13 19 21 20 19 18 19 22 23 23 23 20 17 14 13 15 11 14
Change (%) 32.12 42.65 13.14 -7.50 -2.41 -5.10 7.72 12.91 6.28 -3.11 -0.24 -11.57 -13.38 -19.50 -4.70 14.09 -24.60 22.98
% of Revenue 70.13 61.50 60.46 60.92 58.33 60.27 62.04 57.08 56.24 53.62 51.99 52.37 49.35 44.35 41.95 45.45 56.38 57.61 72.76
SG&A 36 42 48 54 55 65 69 69 69 56 51 49 48 56 56 57 75 68 63
Change (%) 15.64 14.37 13.05 1.87 18.09 6.22 -0.95 0.03 -18.13 -9.37 -2.81 -3.84 18.78 -0.80 2.06 30.82 -9.18 -6.52
% of Revenue 256.27 196.71 155.05 156.11 164.62 205.80 237.13 200.58 175.11 128.59 116.63 114.47 117.27 144.54 168.48 195.48 278.01 342.22 328.52
R&D
Change (%)
% of Revenue
OpEx 44 52 63 72 73 105 107 108 111 77 73 72 69 84 82 81 86 76 68
Change (%) 19.47 19.52 14.48 2.05 44.18 1.88 0.66 2.62 -30.34 -5.51 -1.63 -4.02 21.88 -2.60 -1.30 5.95 -11.68 -10.64
% of Revenue 310.10 245.91 202.55 206.50 218.14 332.96 367.97 316.31 283.31 177.02 167.40 166.28 170.05 215.05 246.13 276.17 318.10 380.78 349.39
Operating Income -30 -31 -32 -37 -40 -74 -78 -74 -72 -34 -29 -29 -28 -45 -49 -52 -59 -56 -48
Change (%) 4.62 1.99 16.61 7.16 86.27 6.04 -5.48 -2.90 -53.16 -12.56 -2.62 -0.80 58.28 8.09 6.05 13.88 -5.01 -13.50
% of Revenue -210.10 -145.91 -102.55 -106.50 -118.14 -232.96 -267.97 -216.31 -183.31 -77.02 -67.40 -66.28 -70.05 -115.05 -146.13 -176.17 -218.10 -280.78 -249.39
Interest Expense -0 -0 -0 -0 -0 -0 -0 -1 -2 -3 -5 -6 -5 -1 -1 -2 -1 -1 -1
Change (%) 2,062.66 23.93 -6.63 25.93 -82.35 438.89 231.19 51.75 66.72 39.28 34.03 -10.89 -82.91 40.37 43.72 -24.25 -13.53 -30.38
% of Revenue -0.09 -1.32 -1.12 -0.93 -1.22 -0.23 -1.33 -3.76 -4.98 -7.45 -10.39 -14.06 -13.35 -2.37 -3.90 -6.38 -5.25 -6.15 -4.40
Net Income -30 -31 -32 -37 -40 -74 -78 -75 -74 -37 -34 -32 -31 -45 -49 -53 -60 -57 -49
Change (%) 4.82 2.20 16.54 7.32 85.41 6.47 -4.33 -1.97 -49.91 -8.84 -4.65 -3.22 45.96 8.90 7.38 13.44 -5.30 -14.03
% of Revenue -209.97 -146.09 -102.89 -106.79 -118.65 -232.87 -268.96 -219.73 -187.99 -84.47 -77.06 -74.19 -76.50 -115.87 -148.28 -181.01 -223.23 -286.52 -252.94

Source: Capital IQ

Other Listings
DE:28L € 0.00
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista